ClinicalTrials.gg
Active, not recruitingNCT07934524NFB:CBT-ASDUpdated Nov 13, 2026

Comparison of Neurofeedback and Behavioral Therapy in Children With Autism Spectrum Disorder

An interventional study of Neurofeedback and Cognitive Behavioral Therapy (CBT) in Autism Spectrum Disorder, sponsored by Shaheed Zulfiqar Ali Bhutto Medical University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 8 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Shaheed Zulfiqar Ali Bhutto Medical University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2026, registered Oct 2026).
Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
8 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies in Autism Spectrum Disorder with a site in Pakistan — 16 open to participants now, 20 under way, none of them phase 3. Autism Spectrum Disorder · Pakistan.

Planned enrollment
11th of 48
62 · median 36
Started
2026
with 11 others
No phase
47 of 50
14 open now
Primary completion
2026-11
later than 16 of 19 live
Registered
49th of 50
by date
Lead sponsor
2 of 50
Shaheed Zulfiqar Ali Bhutto Medical University

Among the 50 studies in Autism Spectrum Disorder with a site in Pakistan, this one is the 11th largest by planned enrollment of the 48 interventional ones that give a count, is one of 12 that started in 2026, is one of 47 with no phase, reaches primary completion later than 16 of the 19 other live ones, and was the 49th registered.

Autism Spectrum Disorder

1,728 studies on the registry are indexed under Autism Spectrum Disorder; 500 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

16 of the 50 studies in Autism Spectrum Disorder with a site in Pakistan are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 349 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 294 (84%) stop at 75 or younger; 298 take children under 18; 92 take healthy volunteers.

This study: 8 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Autism Spectrum Disorder with a site in Pakistan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if neurofeedback therapy works better than cognitive behavioral therapy (CBT) for improving thinking skills (cognitive function) in children aged 8 to 14 years with Autism Spectrum Disorder who have low support needs. The main questions it aims to answer are:

Does neurofeedback improve cognitive function more than CBT? Does neurofeedback improve emotion, grip force, autism severity and intelligence quotient more than CBT?

Researchers will compare neurofeedback with CBT to see if one leads to greater improvement after the therapeutic sessions.

Participants will be randomly placed in either the neurofeedback group or the CBT group Attend 15 sessions twice a week for about 7 to 8 weeks (neurofeedback sessions last 15 to 20 minutes and CBT sessions last about 50 minutes) Complete tests of thinking skills, emotion, grip strength, autism severity and intelligence before intervention and again after the final session.

Read the detailed description

Rationale:

Numerous studies have shown the positive results of cognitive behavioral therapy and neurofeedback therapy upon the symptoms of autism spectrum disorder. Neurofeedback helps in improving cognitive and executive functions of children suffering from ASD. The current literature lacks comparative studies for the interventions used in ASD. Our aim is to compare the effectiveness of Neurofeedback and CBT to analyze the cognitive functions. Moreover, we will compare the sensorimotor domain that has not been explored earlier in relation to ASD.

Our study will be utilizing the digital objective tools of assessment whereas, previous studies have utilized subjective assessment tools. The test will be performed by a child (participant) whereas, in previous studies, parents and teachers reported the improvement in symptoms.

Design:

A randomized controlled trial with two parallel groups. Sixty-two children aged 8 to 14 years with autism spectrum disorder and low support needs are allocated 1:1 (31 per group). Allocation is concealed. Outcome assessors do not know the group allocation. Children and therapists cannot be masked because the two treatments look different.

Setting:

Department of Physiology, Federal Medical College, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan. Children are recruited from the outpatient department at the Pakistan Institute of Medical Sciences and from special and inclusive education institutions in Islamabad. Parents give written informed consent.

Interventions:

Neurofeedback group: 15 sessions of 15 to 20 minutes twice a week for about 7 to 8 weeks, using a BEE Medic neurofeedback system with an EEG amplifier. The child receives visual or audio feedback of their own brain activity and learns to regulate it. CBT group: 15 sessions of about 50 minutes twice a week for about 7 to 8 weeks, with a written session guide. Children may continue stable medication and usual school support. Starting any new therapy during the trial is not permitted.

Outcomes:

The primary outcomes are changes in Cognitive function (measured with the NIH Toolbox version 3) cognition battery and Grip force as a measure of motor output (digital handheld dynamometer).

Secondary outcomes are the Emotion domain (NIH Toolbox Emotion Battery), Autism symptom severity (CARS-II) and Intelligence Quotient (Colored Progressive Matrices). All outcomes are measured before treatment and again after the final session.

Analysis:

Paired t-tests compare scores before and after treatment within each group. Independent t-tests compare the change between the two groups. Analysis uses SPSS version 25 with significance at p ≤ 0.05. The main analysis includes children who complete at least 12 of the 15 sessions in both assessments. A second analysis includes all randomized children. Secondary outcomes are interpreted cautiously because the trial is not powered to prove them.

Sample size:

The sample size was calculated with the WHO sample size calculator, with a 5% level of significance, 80% power of test. Population standard deviation of 17 and anticipated mean cognitive domain scores in the behavioral therapy and neurofeedback group. based on these values, the required sample size was calculated to be 31 participants in each group resulting in a total sample size of 62 participants.

Safety. Both treatments are non-invasive. A little discomfort might be mild scalp irritation from the electrode gel and paste. Adverse events will be recorded at every session and reported to the supervisor within 48 hours.

Ethics and reporting:

The study is approved by the ERB at SZABMU with approval number (No.F.1-1/2015/ERB/SZABMU/1407).

Results will be published whether they are positive or negative. De-identified data will be shared on reasonable request after publication.

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • ASD
04

Who can participate

Ages eligible
8 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed cases of ASD by the registered clinician/ clinical psychologist using the standardized diagnostic criteria particularly through (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) criteria or ADOS-2 (Autism Diagnostic Observation Schedule, 2nd edition)
  • ASD cases of both genders ranging from 8 - 14 years in age.
  • Autism with low support needs (Level 1)
  • Written from a parent or guardian

Exclusion criteria

Exclusion Criteria:

  • Comorbid cases with psychiatric illness.
  • Children enrolled in other clinical trials.
  • Level 3 ASD (High level of support needed)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Neurofeedback

    15 neurofeedback sessions of 15 to 20 minutes, twice a week for about 7 to 8 weeks. The child receives visual or audio feedback of their own EEG so that they learn to regulate cortical activity.

    Device: Neurofeedback

  • Active comparator
    Cognitive Behavioral Therapy

    15 sessions of CBT of about 50 minutes, twice a week for about 7 to 8 weeks. The child receives sessions with incorporating their special interests, preferred topics, motivators, social stories, sensory-soothing items, slow step by step exposures paired with coping skills to challenge distressing thought patterns or rigid thinking.

    Behavioral: Cognitive Behavioral Therapy (CBT)

Interventions

  • DeviceNeurofeedback

    Neurofeedback (EEG biofeedback) is delivered with a BEE Medic neurofeedback system (Germany) and an EEG differential amplifier. The scalp is prepared with Nuprep gel and electrodes are attached with Ten20 conductive paste. The child sits in front of a screen while the system records their EEG in real time and converts it into visual or audio feedback. Desirable brain activity is rewarded and undesirable activity is not, so the child gradually learns to regulate cortical activity.

    Also known as: EEG Biofeedback

  • BehavioralCognitive Behavioral Therapy (CBT)

    Evidence-based frameworks like Behavioral and Cognitive-Behavioral Interventions help children understand the connection between their actions and outcomes, using visual aids, predictable routines and self-regulatory scripts to ease transitions and build flexibility, focuses on gaining practical communication, building independence and supporting emotional regulation through structured, encouraging environments.

    Also known as: Cognitive Behavioral Interventions (CBI), Acceptance and Commitment Therapy (ACT), Cognitive Behavioral Play Therapy (CBPT), Unstuck and On Target (UOT)

06

What researchers measure

Primary outcomes

  1. Change in the Fluid Cognition Composite on the National Institutes of Health NIH Toolbox Cognition Battery (Version 3)

    Visual Reasoning: Nonverbal visual reasoning is assessed using the NIH Toolbox V3 Visual Reasoning (VR) Test, administered on iPad. Participants identify patterns and rules in visual stimuli, select the response option that best completes or matches the target image. The test is computer-adaptive and takes 7 minutes. Results are reported as an age-corrected standard score (normative mean = 100, SD = 15), where higher scores indicate better visual reasoning ability. Change is calculated as the post-intervention score minus the baseline score.

    Time frame: Baseline and within one week after the final (15th) session, about 10 weeks

  2. Change in Positive Affect (Emotion domain) on the National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function, Version 3 (NIH Toolbox V3)

    Positive Affect Computer Adaptive Test (Ages 8-12): Positive affect, defined as feelings of pleasurable engagement such as happiness, joy, interest and contentment is assessed using the NIH Toolbox V3 Positive Affect Computer Adaptive Test (CAT) for ages 8-12, self-reported by participants on iPad. The CAT selects items based on previous responses, giving a precise score with fewer questions. Results are reported as a T-score (normative mean = 50, SD = 10). Scores range from a minimum of \[MIN\] to a maximum of \[MAX\]. Higher scores indicate greater positive affect (better outcome). Change is calculated as the post-intervention score minus the baseline score.

    Time frame: Baseline and within one week after the final session, about 10 weeks

Secondary outcomes

  1. Change in Hand Grip Strength measured by Digital Hand Dynamometer

    Maximal isometric hand grip strength is measured in kilograms (kg) using a Camry electronic hand dynamometer as a form of motor output analysis. Participants are seated with the shoulder adducted, elbow flexed at 90° and forearm in a neutral position. Three maximal trials are performed with a rest interval between trials and the mean value is recorded. Change is calculated as the post-intervention value minus the baseline value. Positive values indicate improvement showing increase in kg on digital dynamometer as a result.

    Time frame: baseline test and after intervention (about 10 weeks)

  2. Change in Inhibitory Control and Attention Score on the National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function, Version 3 (NIH Toolbox V3) Flanker Inhibitory Control and Attention Test

    Inhibitory control and attention are assessed with the NIH Toolbox V3 Flanker Inhibitory Control and Attention Test (app version 3.1), administered on iPad in approximately 3 minutes. Participants indicate the direction of a central stimulus (arrow, or fish for younger children) that is flanked by stimuli pointing in the same (congruent) or opposite (incongruent) direction. Scoring combines accuracy and reaction time. Results are reported as an age-corrected standard score (normative mean = 100, SD = 15). Scores range from a minimum of \[MIN\] to a maximum of \[MAX\]. Higher scores indicate better inhibitory control and attention (better outcome). Change is calculated as the post-intervention score minus the baseline score.

    Time frame: baseline test then post-intervention, after about 10 weeks

  3. Change in Autism Symptom Severity Measured by the Childhood Autism Rating Scale, Second Edition - Standard Version (CARS2-ST) Total Score

    Autism symptom severity is assessed by a trained clinician using the Childhood Autism Rating Scale, Second Edition - Standard Version (CARS2-ST) based on direct observation of the participant and information from parents and trainer. The scale has 15 items (e.g. relating to socializing, imitation, emotional response, body use, verbal and nonverbal communication, activity level) each rated from 1 (within normal limits for age) to 4 (severely abnormal), with half-point ratings allowed. Item ratings are summed to give a total score ranging from a minimum of 15 to a maximum of 60. Higher scores indicate greater autism symptom severity (worse outcome). Change is calculated as the post-intervention score minus the baseline score; negative values indicate improvement.

    Time frame: baseline and about 10 weeks

  4. Change in Processing Speed Measured by the National Institute of Health Toolbox Speeded Matching Test (Version 3)

    Processing speed is assessed using the NIH Toolbox V3 Speeded Matching (SpM) Test, administered on iPad. Participants select, as quickly as possible, which of four pictures matches a target picture shown at the top of the screen. Administration takes approximately 3 minutes. Results are reported as an age-corrected standard score (normative mean = 100, SD = 15), where higher scores indicate faster processing speed. Change is calculated as the post-intervention score minus the baseline score.

    Time frame: baseline test and post intervention (after about 10 weeks)

  5. Change in Positive Affect (Emotion domain) on the National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function, Version 3 (NIH Toolbox V3) Positive Affect Parent-Report Computer Adaptive Test

    Positive Affect Parent rpt CAT Ages 8-12: Parent-Report Computer Adaptive Test: The child's positive affect, defined as feelings of pleasurable engagement such as happiness, joy, interest and contentment, is assessed using the NIH Toolbox V3 Positive Affect Parent-Report Computer Adaptive Test (CAT) for ages 8-12. A parent initilly then parent and trainer rates the child's recent feelings on iPad. The CAT selects items based on previous responses, giving a precise score with fewer questions. Results are reported as a T-score (normative mean = 50, SD = 10). Scores range from a minimum of \[MIN\] to a maximum of \[MAX\]. Higher scores indicate greater positive affect (better outcome). Change is calculated as the post-intervention score minus the baseline score.

    Time frame: Baseline scoring and then after about 10 weeks

Other outcomes

  1. Change in Nonverbal Reasoning Ability Measured by Raven's Colored Progressive Matrices (CPM) Total Raw Score

    Nonverbal reasoning (fluid intelligence)/ IQ is assessed using Raven's Colored Progressive Matrices (CPM), a nonverbal test in which the participants select the missing piece that completes a visual pattern. The test consists of 36 items in three sets (A, Ab, and B) with 12 items each, scored 1 for a correct and 0 for an incorrect response. The total raw score ranges from a minimum of 0 to a maximum of 36. There are percentile charts as well for comparison to the typical developing children. In scoring, Higher scores indicate better nonverbal reasoning ability (better outcome). Change is calculated as the post-intervention score minus the baseline score.

    Time frame: baseline and about 10 weeks

07

Study locations

1 site
  • Federal Medical College, Hanna Road, G-8/4,Islamabad, Pakistan.
    Islamabad, Federal Capital 44000, Pakistan
08

References and documents

Publications

  • Christ SE, Stichter JP, O'Connor KV, Bodner K, Moffitt AJ, Herzog MJ. Social Skills Intervention Participation and Associated Improvements in Executive Function Performance. Autism Res Treat. 2017;2017:5843851. doi: 10.1155/2017/5843851. Epub 2017 Sep 17. PubMed 29075533 ↗
  • Saleem S, Habib SH. Neurofeedback Recuperates Cognitive Functions in Children with Autism Spectrum Disorders (ASD). J Autism Dev Disord. 2024 Aug;54(8):2891-2901. doi: 10.1007/s10803-023-06037-z. Epub 2023 Jun 14. PubMed 37314667 ↗
  • Matsuura N, Ishitobi M, Arai S, Kawamura K, Asano M, Inohara K, Narimoto T, Wada Y, Hiratani M, Kosaka H. Distinguishing between autism spectrum disorder and attention deficit hyperactivity disorder by using behavioral checklists, cognitive assessments, and neuropsychological test battery. Asian J Psychiatr. 2014 Dec;12:50-7. doi: 10.1016/j.ajp.2014.06.011. Epub 2014 Jul 10. PubMed 25440561 ↗

Individual participant data

Plan to share: No — De-identified individual participant data and the analysis plan will only be available on reasonable request once the primary results are published. Requests go to the corresponding author and are subject to institutional approval and the terms of parental consent. Timeframe for sharing may be the beginning 6 months after publication of the primary results.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.

Of 802 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 7 months is below that.

Counting every sponsor, half of 825 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2026
First posted
Nov 13, 2026
StartActual
Mar 25, 2026
Primary completionEst.
Nov 20, 2026
CompletionEst.
Dec 1, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934524
Lead sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
Responsible party
Dr. Maryam Nasim (Postgraduate Researcher, Shaheed Zulfiqar Ali Bhutto Medical University) — Principal investigator
First posted
Nov 13, 2026
Start date
Mar 25, 2026
Primary completion
Nov 20, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Nov 13, 2026

Study contacts

Prof. Dr. Shemaila Saleem, PhD
study director · Shaheed Zulfiqar Ali Bhutto Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion